3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
6
Genitourinary
3
Tumor-Agnostic
2
Thoracic
2
Breast
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
56
Specimen Handling
28
Biopsy
27
Magnetic Resonance Spectroscopy
26
Paclitaxel
22
Blood Specimen Collection
21
Nivolumab
20
atezolizumab
18
Standard of Care
18
Carboplatin
18
Surveys and Questionnaires
17
Bevacizumab
17
Oxaliplatin
13
Fluorouracil
13
Cisplatin
13
Radiotherapy
12
Radiosurgery
12
Cyclophosphamide
12
Pemetrexed
11
Leucovorin
11
Irinotecan
10
Gemcitabine
10
Docetaxel
10
Capecitabine
10
trastuzumab deruxtecan
8
olaparib
8
Taxes
8
Ipilimumab
8
durvalumab
7
Trastuzumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
rucaparib
×
Tumor-Agnostic
×
1 year
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled